Anti-Human IL-6R (Sarilumab) – PE
Anti-Human IL-6R (Sarilumab) – PE
Product No.: LT1704
Product No.LT1704 Clone Hu137 Target IL-6 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Interleukin-6, CDF; HGF; HSF; BSF2; BSF-2; IFNB2; IFN-beta-2 Isotype Human IgG1κ Applications FA , FC , IHC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Product Concentration 0.2 mg/ml Formulation This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm) RRIDAB_2893929 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? IHC (Paraffin) IHC (Frozen) Additional Reported Applications For Relevant Conjugates ? FA WB B N Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Sarilumab. Sarilumab binds to the transmembrane and soluble forms of the IL-6 receptor. This product is for research use only. Background IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects. Antigen Distribution IL-6R is ubiquitously expressed. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Cell Biology . Immunology . Innate Immunity . Neuroscience . Other Molecules Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Sarilumab biosimilars are used as calibration standards and reference controls in PK bridging ELISAs to ensure accurate and comparable measurement of Sarilumab concentrations in serum samples across biosimilar and reference products. When measuring drug concentration in serum (e.g., for pharmacokinetic (PK) studies), the best practice is to develop a single PK ELISA method that uses a single analytical standard—often the biosimilar itself—as the calibrator for both the biosimilar and reference products (such as the originator drug). This approach is favored because:
Typical process in a PK bridging ELISA:
Use of reference controls:
Assay calibration and performance validation:
Industry consensus and guidelines:
Summary Table: Use of Sarilumab Biosimilar in PK Bridging ELISA
In essence, research-grade Sarilumab biosimilars serve as the standardized calibration agent and reference control in PK bridging ELISA assays, enabling direct and reliable measurement of drug concentrations for both biosimilar and reference Sarilumab products in clinical development and bioequivalence studies. A conjugated Sarilumab biosimilar (e.g., PE or APC-labeled) is used in standard flow cytometry protocols to directly detect and quantify the surface expression of the IL-6 receptor (IL-6R) on human cells, or to assess the binding capacity of the biosimilar antibody to IL-6R. The core elements of the standard protocol, as supported by biosimilar manufacturer guidelines and research-use datasheets, include the following steps: 1. Cell Preparation
2. Blocking (Optional but Recommended)
3. Antibody Staining
4. Washing
5. Data Acquisition
6. Controls
7. Data Analysis
Key considerations:
References to protocols and datasheets:
These protocols are intended for research use only and not for diagnostic or therapeutic procedures. Biopharma companies typically conduct a comprehensive suite of structural and functional analytical assays to confirm the similarity of a biosimilar to its originator (reference) drug. The main goals are to demonstrate that the biosimilar and the originator are highly similar in their primary structure, higher-order structure, post-translational modifications, impurities, and, crucially, biological function. Key analytical assays used:
These assays are not only performed side-by-side with multiple lots of the originator, but results must fall within an appropriate range to confirm high similarity. Role of Leinco biosimilars in these studies: Leinco is a supplier that manufactures biosimilar reference antibodies and reagents, often used as analytical reference standards in these comparability studies.
In summary:
For further details or methodological specifics, refer to regulatory guidelines (e.g., FDA, EMA) as well as biosimilar workflow descriptions from leading vendors and scientific reviews. References & Citations1. Kevzara (sarilumab) injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; Bridgewater, NJ: sanofi-aventis U.S.; May 2017. 2. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313. 3. "Northwell Health Initiates Clinical Trials of 2 COVID-19 Drugs". 21 March 2020. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT1700 | |
LT1703 | |
LT1704 | |
LT1702 | |
LT1701 | |
LT1711 | |
LT1706 | |
LT1705 | |
LT1707 |
